Details for Patent: 9,511,056
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,511,056 protect, and when does it expire?
Patent 9,511,056 protects HARVONI and is included in two NDAs.
Protection for HARVONI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and thirty-six patent family members in thirty-eight countries.
Summary for Patent: 9,511,056
| Title: | Antiviral compounds |
| Abstract: | The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. |
| Inventor(s): | Bacon; Elizabeth M. (Burlingame, CA), Canales; Eda (San Mateo, CA), Cho; Aesop (Mountain View, CA), Cottell; Jeromy J. (Redwood City, CA), Desai; Manoj C. (Pleasant Hill, CA), Graupe; Michael (Pacifica, CA), Guo; Hongyan (San Mateo, CA), Halcomb; Randall L. (Foster City, CA), Kato; Darryl (San Francisco, CA), Kim; Choung U. (San Carlos, CA), Kirschberg; Thorsten A. (Redwood City, CA), Krygowski; Evan S. (Belmont, CA), Lazerwith; Scott E. (San Francisco, CA), Link; John O. (San Francisco, CA), Liu; Hongtao (Foster City, CA), Liu; Qi (Union City, CA), Mackman; Richard L. (Millbrae, CA), Mitchell; Michael L. (Hayward, CA), Parrish; Jay P. (Redwood City, CA), Pyun; Hyung-Jung (Fremont, CA), Saugier; Joseph H. (Livermore, CA), Schroeder; Scott D. (Foster City, CA), Sun; Jianyu (Surrey, CA), Taylor; James G. (San Mateo, CA), Trenkle; James D. (Oakland, CA), Tse; Winston C. (Redwood City, CA), Vivian; Randall W. (San Mateo, CA), Watkins; William J. (Saratoga, CA), Xu; Lianhong (Palo Alto, CA) |
| Assignee: | Gilead Pharmasset LLC (Foster City, CA) |
| Application Number: | 14/280,478 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,511,056
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-002 | Aug 28, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-001 | Oct 10, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,511,056
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 3622 | See Plans and Pricing | |||
| Argentina | 076765 | See Plans and Pricing | |||
| Australia | 2010249043 | See Plans and Pricing | |||
| Brazil | 122014012810 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
